Investment Rating - The report has downgraded the investment rating to "Outperform" [2][6] Core Insights - The company achieved a revenue of 1.058 billion yuan in 2025, representing a year-on-year growth of 21.8%, and a net profit attributable to the parent company of 237 million yuan, up 33.9% year-on-year [2][5] - The diabetes and hypertension segments showed stable growth, with diabetes revenue increasing by 18.2% and hypertension revenue by 28.3% in 2025 [3][4] - The company has a robust pipeline with over 30 products in development, including DYX116, which is nearing completion of its Phase I clinical trials for diabetes treatment [4][6] Financial Summary - Revenue projections for 2026-2028 are adjusted to 1.183 billion yuan, 1.308 billion yuan, and 1.435 billion yuan, respectively, with corresponding net profits of 238 million yuan, 252 million yuan, and 264 million yuan [5][7] - The gross margin is expected to decline slightly from 84.1% in 2025 to 81.8% by 2028, reflecting potential pressures from future product pricing and R&D investments [5][8] - The earnings per share (EPS) forecast for 2026-2028 is set at 2.03 yuan, 2.15 yuan, and 2.25 yuan, with price-to-earnings (P/E) ratios of 16.9, 16.0, and 15.3, respectively [2][5]
德源药业（920735）：北交所信息更新：仿制药糖尿病、高血压类稳增，DYX116（降糖）I期完成在即